Molecular intrinsic subtypes, genomic, and immune landscapes of BRCA-proficient but HRD-high ER-positive/HER2-negative early breast cancers.

Date publication

novembre 2022

Journal

Breast cancer research : BCR

Auteurs

Membres identifiés du Cancéropôle Est :
Dr ARNOULD Laurent , Dr BOIDOT Romain , Pr GHIRINGHELLI François , Dr LADOIRE Sylvain , Mme TRUNTZER Caroline , Dr DESMOULINS Isabelle , Dr DERANGERE Valentin , Dr HENNEQUIN Audrey , Dr MAYEUR Didier , Dr GALLAND Loïck

Tous les auteurs :
Ballot E, Galland L, Mananet H, Boidot R, Arnould L, Desmoulins I, Mayeur D, Kaderbhai C, Ilie S, Hennequin A, Bergeron A, Derangère V, Ghiringhelli F, Truntzer C, Ladoire S

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/36401316

Résumé

The vast majority of research studies that have described the links between DNA damage repair or homologous recombination deficiency (HRD) score, and tumor biology, have concerned either triple negative breast cancers or cancers with mutation of BRCA 1/2. We hypothesized that ER + /HER2- early breast tumors without BRCA 1/2 mutation could have high HRD score and aimed to describe their genomic, transcriptomic, and immune landscapes.

Mots clés

BRCA, ER-positive breast cancer, Early breast cancer, Exome, HRD score, Homologous recombination, NGS, Signature 3

Référence

Breast Cancer Res. 2022 11 18;24(1):80